Help us: Donate
Follow us on:



LEAF Meets Mikhail Batin


The rejuvenation research community is very diverse. Despite each of us having their favorite projects or directions of activity, the achievement of our common goal – the extended period of health and productivity – is highly dependent on this diversity. We need advocacy organizations to educate the public and fundraise actively, in order to support fundamental research.

Once these fundamental studies are done, we need biotechnology startups to play their role in taking these new potential therapies through preclinical testing. Then bigger companies or venture investors need to support these startups with clinical trials in order to get promising interventions approved by regulatory authorities. Each stage is necessary to transform an idea into a treatment.

Regardless of what aspect of this process a person or group works within, it is always nice to meet like-minded people who are trying to find a way to achieve results sooner. There are many drugs which are already approved to treat specific diseases, but which are also known to have the potential to address aspects of the aging process. Sadly, most have not yet been tested in healthy middle-aged people in clinical trials, so we cannot be sure about their effect on the human lifespan.

So, should we just wait for a research organization or pharmaceutical company to do this? Mikhail Batin*, the head of Science for Life Extension Foundation, says no. Recently in the US to attend the conference The Biology of Aging: Advances in Therapeutic Approaches to Extend Healthspan”, Mikhail also stopped by to visit LEAF President Keith Comito and discuss life extension activities in Russia and Mikhail’s new ambitious project – Open Longevity.

Mikhail believes there are alternative ways to organize pilot clinical trials and obtain crucial data about promising geroprotectors – information that every member of our community would benefit from. The solution is simple and elegant: members of a local community can become participants of a trial themselves, while a specialized patient organization will ensure proper procedures (study protocol development and observation, analysis of the data and preparation of a publication) are followed.

This is the main goal of Russian initiative Open Longevity, started few months ago. So far, Open Longevity is planning to test a combination of statins with sartans as a pilot project; the team is open to discussion regarding the experiment design and protocol. They are also considering calorie restriction and the well-known effects of metformin. All these interventions are relatively safe and easy to apply. The data will be accurately collected, and the project research team will publish the results in a peer-reviewed journal to share with the global community.

We wish Open Longevity every possible success and appreciate Mikhail’s team taking the time to connect with LEAF to discuss their work.

 *Mikhail Batin is one of the longest active life extension advocates in Russia. He started his activities back in 2008 when the Foundation Science for Life Extension was first registered with the mission to support the scientific research to develop radical life extension techniques.

Since then, he became author and co-author of numerous books and articles promoting the idea of life extension, directly supported several research projects and organized three international conferences “Genetics of aging and longevity”, helping to establish international bonds between Russian and foreign star researchers on aging.


Related Organizations

About the author
Elena Milova

Elena Milova

Elena has been a longevity activist and advocate since 2013, when she first started to organize educational events to make new evidence-based methods of healthy life extension more popular. The last few years have seen Elena leading some successful projects in Russia, aimed at spreading the idea of healthy longevity among decision makers as well as the general public. Several years of lobbying resulted in the inclusion of her propositions in the strategic program documents of the Russian Federation related to the problems of the elderly. She is a co-author of the book “Aging Prevention for All” (in Russian, 2015), where, among other topics, she is sharing how to facilitate the adoption of the healthy lifestyle to promote the period of good health. In 2015, Elena helped to shape and coordinate the successful crowdfunding campaign of the Major Mouse Testing Program – a study of Senolytic drug combinations on mouse lifespan. In 2017 at LEAF, Elena led a successful advocacy project to include the problems of the elderly into the WHO’s 13th Programme of Work . Previously Elena has worked as a project manager in the pharmaceutical and advertisement industries, helping to promote new drugs and therapies. This experience helped her to realize that the existing therapies were not 100% effective and could not completely stop age-related diseases – which has ignited an interest for the development of innovative therapies. Elena graduated with a bachelor’s in both psychology and foreign languages and is now working to earn her MBA at the oldest Russian business school MIRBIS. Elena left her Board and staff position at LEAF in January 2022 to pursue other endeavours.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.